Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 51, 2012, Pages 21134-21139

  Pamplona, Fabricio A ^a,b   Ferreira, Juliano ^c   De Lima, Octávio Menezes ^a   Duarte, Filipe Silveira ^a   Bento, Allisson Freire ^a   Forner, Stefânia ^a   Villarinho, Jardel G ^c   Bellochio, Luigi ^d,e   Wotjak, Carsten T ^f   Lerner, Raissa ^g   Monory, Krisztina ^g   Lutz, Beat ^g   Canetti, Claudio ^h   Matias, Isabelle ^d,e   Calixto, João Batista ^a   Marsicano, Giovanni ^d,e   Guimarães, Marilia Z P ^h   Takahashi, Reinaldo N ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b D OR INSTITUTE FOR RESEARCH AND EDUCATION IDOR   (Brazil)

^c FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^d INSERM   (France)

^e INSTITUT FRANÇOIS MAGENDIE   (France)

^f MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^g UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^h FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Allosteric modulation; GPCR; Inflammation; Neuroprotection; Psychopharmacology

Indexed keywords

AMYLOID BETA PROTEIN; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; LIPOXIN; LIPOXIN A;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MEMORY DISORDER; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPATIAL MEMORY;

EID: 84871380135     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1202906109     Document Type: Article

References (54)

1. Pacher P, Bátkai S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58(3):389-462.
2. Howlett AC, et al. (2004) Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47(Suppl 1):345-358.
3. Glass M, Northup JK (1999) Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol Pharmacol 56(6):1362-1369.
4. Gonsiorek W, et al. (2000) Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: Antagonism by anandamide. Mol Pharmacol 57(5):1045-1050.
5. Hillard CJ, et al. (1999) Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 289(3):1427-1433.
6. Reggio PH (2003) Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors. Curr Pharm Des 9(20):1607-1633.
7. Kenakin T (2007) Functional selectivity through protean and biased agonism: Who steers the ship? Mol Pharmacol 72(6):1393-1401.
8. Neubig RR, Spedding M, Kenakin T, Christopoulos A; International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification (2003) International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 55(4):597-606.
9. Price MR, et al. (2005) Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 68(5):1484-1495.
10. Nomura DK, et al. (2011) Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334(6057):809-813.
11. Kozak KR, Marnett LJ (2002) Oxidative metabolism of endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 66(2-3):211-220.
12. Serhan CN, Hamberg M, Samuelsson B (1984) Lipoxins: Novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci USA 81(17):5335-5339.
13. McMahon B, Mitchell S, Brady HR, Godson C (2001) Lipoxins: Revelations on resolution. Trends Pharmacol Sci 22(8):391-395.
14. Chiang N, Takano T, Arita M, Watanabe S, Serhan CN (2003) A novel rat lipoxin A4 receptor that is conserved in structure and function. Br J Pharmacol 139(1):89-98.
15. Kim SJ (1988) Formation of lipoxins by alveolar macrophages. Biochem Biophys Res Commun 150(2):870-876.
16. Sri Kantha S, et al. (1994) Effects of prostaglandin D2, lipoxins and leukotrienes on sleep and brain temperature of rats. Prostaglandins Leukot Essent Fatty Acids 51(2):87-93.
17. Shearman MS, et al. (1988) Isolation of protein kinase C subspecies from a preparation of human T lymphocytes. FEBS Lett 234(2):387-391.
18. Shearman MS, Naor Z, Sekiguchi K, Kishimoto A, Nishizuka Y (1989) Selective activation of the gamma-subspecies of protein kinase C from bovine cerebellum by arachidonic acid and its lipoxygenase metabolites. FEBS Lett 243(2):177-182.
19. Williams JH, Bliss TV (1988) Induction but not maintenance of calcium-induced long-term potentiation in dentate gyrus and area CA1 of the hippocampal slice is blocked by nordihydroguaiaretic acid. Neurosci Lett 88(1):81-85.
20. de Oliveira Alvares L, et al. (2006) AM251, a selective antagonist of the CB1 receptor, inhibits the induction of long-term potentiation and induces retrograde amnesia in rats. Brain Res 1075(1):60-67.
21. Murillo-Rodríguez E, et al. (1998) Anandamide modulates sleep and memory in rats. Brain Res 812(1-2):270-274.
22. Pamplona FA, Menezes-de-Lima O, Jr., Takahashi RN (2010) Aspirin-triggered lipoxin induces CB1-dependent catalepsy in mice. Neurosci Lett 470(1):33-37.
23. Howlett AC, et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54(2):161-202.
24. Christopoulos A, Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54(2):323-374.
25. Aliberti J, Serhan C, Sher A (2002) Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection. J Exp Med 196(9):1253-1262.
26. Bafica A, et al. (2005) Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production. J Clin Invest 115(6):1601-1606.
27. Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML (2005) Prevention of Alzheimer's disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation. J Neurosci 25(8):1904-1913.
28. van der Stelt M, et al. (2006) Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: Effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci 63(12):1410-1424.
29. Serhan CN, Chiang N, Van Dyke TE (2008) Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8(5):349-361.
30. Zurier RB, et al. (2009) Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4. FASEB J 23(5):1503-1509.
31. Horswill JG, et al. (2007) PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br J Pharmacol 152(5):805-814.
32. Kenakin TP (2009) '7TM receptor allostery: Putting numbers to shapeshifting proteins. Trends Pharmacol Sci 30(9):460-469.
33. Devane WA, et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
34. Di Marzo V, Bisogno T, De Petrocellis L (2001) Anandamide: Some like it hot. Trends Pharmacol Sci 22(7):346-349.
35. Savinainen JR, Järvinen T, Laine K, Laitinen JT (2001) Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB(1) receptor-dependent G-protein activation in rat cerebellar membranes. Br J Pharmacol 134(3):664-672.
36. Tanimura A, et al. (2010) The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. Neuron 65(3):320-327.
37. Darmani NA, et al. (2005) Cisplatin increases brain 2- arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. Neuropharmacology 49(4):502-513.
38. Maccarrone M, et al. (2008) Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci 11(2):152-159.
39. Makara JK, et al. (2005) Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci 8(9):1139-1141.
40. Milligan G (2003) Principles: Extending the utility of [35S]GTP gamma S binding assays. Trends Pharmacol Sci 24(2):87-90.
41. Glass M, Felder CC (1997) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: Evidence for a Gs linkage to the CB1 receptor. J Neurosci 17(14):5327-5333.
42. Lauckner JE, Hille B, Mackie K (2005) The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc Natl Acad Sci USA 102(52):19144-19149.
43. Ahn KH, Mahmoud MM, Kendall DA (2012) Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high af finity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation. J Biol Chem 287(15):12070-12082.
44. Russo R, et al. (2007) The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther 322(1):236-242.
45. Craib SJ, Ellington HC, Pertwee RG, Ross RA (2001) A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus. Br J Pharmacol 134(1):30-37.
46. Edgemond WS, Hillard CJ, Falck JR, Kearn CS, Campbell WB (1998) Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): Their affinities for cannabinoid receptors and pathways of inactivation. Mol Pharmacol 54(1):180-188.
47. van der Stelt M, et al. (2002) Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: Conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. J Med Chem 45(17):3709-3720.
48. Eljaschewitsch E, et al. (2006) The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49(1):67-79.
49. Marsicano G, et al. (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302(5642):84-88.
50. Monory K, et al. (2006) The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51(4):455-466.
51. Albayram O, et al. (2011) Role of CB1 cannabinoid receptors on GABAergic neurons in brain aging. Proc Natl Acad Sci USA 108(27):11256-11261.
52. Caputo CB, Salama AI (1989) The amyloid proteins of Alzheimer's disease as potential targets for drug therapy. Neurobiol Aging 10(5):451-461.
53. Pamplona FA, Takahashi RN (2012) Psychopharmacology of the endocannabinoids: Far beyond anandamide. J Psychopharmacol 26(1):7-22.
54. Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4(11):873-884.